Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis
Antimicrobial Agents and Chemotherapy · 14.12.2023 · 67 (12)
DOI: 10.1128/aac.00916-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 14.12.2023. Verfasst von Stefan Roepcke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cognigen Division of Simulations Plus, Inc., Buffalo, New York, USA. Hauptthemen laut MEDLINE: Candidemia, Candidiasis, Invasive. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mundipharma Research Limited, Cidara Therapeutics (Cidara).
Abstract (Originalsprache)
Rezafungin is a chemically and metabolically stable echinocandin with a longer half-life than other echinocandins, allowing for a once-weekly intravenous infusion versus a daily infusion. Rezafungin is approved in the US for the treatment of candidemia and/or invasive candidiasis and is in development for the prevention of invasive fungal disease caused by Candida , Aspergillus , and Pneumocystis spp. in immunosuppressed patients. A population pharmacokinetic (PPK) model was developed using data from five Phase 1, one Phase 2, and one Phase 3 study. The model found to best describe the available data was a three-compartment PPK model with first-order elimination characterized by the parameters clearance (CL), central volume (V1), peripheral volume (V23), intercompartmental clearance 1, and intercompartmental clearance 2. The variability model included correlated interindividual variability in CL, V1, and V23 and a proportional residual variability model. The following statistically significant covariates were identified: albumin concentrations on V23; body surface area (BSA) on CL, V1, and V23; and disease state on CL and V1. Disease states were defined as patients from the Phase 2 and Phase 3 studies and hepatically impaired subjects. Covariates of BSA, disease state, or albumin, included in the final model, were not associated with clinically meaningful changes in PK, nor were any other patient factors, indicating that a common dose regimen is adequate for all adult patients. Target attainment simulations were performed to estimate the probability of achieving PK/pharmacodynamic targets across the range of minimum inhibitory concentration values for six species of Candida .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cognigen Division of Simulations Plus, Inc., Buffalo, New York, USA.
- Mundipharma, Cambridge, United Kingdom.
- Cidara Therapeutics, San Diego, California, USA.
ORCID-Profile: Julie Passarell, Helen Walker, Shawn Flanagan
Förderung
- Mundipharma Research Limited
- Cidara Therapeutics (Cidara)
Zitieren
APA
Roepcke, S., Passarell, J., Walker, H., & Flanagan, S. (2023). Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis. Antimicrobial Agents and Chemotherapy, 67(12). https://doi.org/10.1128/aac.00916-23
Vancouver
Roepcke S, Passarell J, Walker H, Flanagan S. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis. Antimicrobial Agents and Chemotherapy. 2023;67(12). doi:10.1128/aac.00916-23
BibTeX
@article{Roepcke2023,
author = {Roepcke, Stefan and Passarell, Julie and Walker, Helen and Flanagan, Shawn},
title = {Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
volume = {67},
number = {12},
doi = {10.1128/aac.00916-23}
}
EUVIMED